Company / Free Cash Flow
Harmony Biosciences Holdings, Inc. Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$347.9M
FY2025
5-year range
-$75.6M / $347.9M
FY2021-FY2025
Trend
+59.1%
vs FY2024
Sector context
#26 of 194
Health Care
What the data says
Harmony Biosciences Holdings, Inc.'s free cash flow of $348M is higher than 87% of companies in the Health Care sector (FY2025). Improved from $219M to $348M over the past 2 years.
Based on SEC 10-K filings.
$348M in FY2025 with a 3-year CAGR of +34.1%. Top quartile in the Health Care sector.
Improved from $219M to $348M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +34.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 194This company $347.9M Sector average $470.8M
▼
-26.1% below sector average
Key checks
Key Insights
- 3-year CAGR of +34.1%, indicating consistent growth.
- In FY2025, free cash flow increased 59.1% year-over-year.
- Ranks #26 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $347.9M | +59.1% |
| FY2024 | $218.7M | -0.2% |
| FY2023 | $219.1M | +51.8% |
| FY2022 | $144.3M | +290.9% |
| FY2021 | -$75.6M | +0.0% |
| FY2020 | -$75.6M | +0.0% |
| FY2019 | -$75.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026